A melanocortin receptor agonist acting on central pathways rather than on blood flow. Approved as bremelanotide for hypoactive sexual desire disorder in premenopausal women.
FDA-approved as bremelanotide (Vyleesi).
This page summarises how much a compound has been studied. A high publication count is not evidence that something works, is safe, or is legal to obtain where you live. Consult a qualified healthcare provider before acting on anything here.
Our mission is to make peptide research clear, credible, and usable for people who refuse to rely on hype.